title: Helicobacter pylori and anemia with pregnancy.
abstract: METHODS
  Study was conducted in Ain Shams University hospitals on 100 pregnant women with iron-deficiency anemia (IDA), including 50 cases infected with Helicobacter pylori (H. pylori) and 50 cases negative for H. pylori infection. Cases with symptomatic gastritis or hyperemesis gravidarum were not included in the study, obstetric history, sociodemographic and dietary variables were also assessed. Hemoglobin level, serum iron, serum ferritin, total iron binding capacity (TIBC), H. pylori serum antibody, stool analysis to exclude parasitic infection causing IDA, occult blood in stool and ultrasound for the fetus to ensure its cardiac pulsations and to exclude any associated abnormality were all done for all patients. Iron therapy in a fixed dose was given to all patients for 1 month. Response was estimated and statistical comparison was done between both groups. Eradication of H. pylori was done in positive cases by triple therapy in the second trimester and iron therapy was given after treatment in the same dose for another month. Their response to treatment after eradication was compared to their response to iron therapy prior to H. pylori eradication.
  
  
  RESULTS
  Hb levels, serum iron, serum ferritin were lower and TIBC was higher in H. pylori-infected cases than negative ones. The average rise of Hb in cases negative to H. pylori was higher than those positive to H. pylori. After comparing response of cases infected with H. pylori to iron therapy before and after eradication of H. pylori, it was found that rise of Hb was higher after treatment than before eradication of H. pylori.
  
  
  CONCLUSIONS
  Response to iron therapy in cases of iron deficiency anemia in patients without H. pylori infection was better than those infected with H. pylori. H. pylori eradication in the infected cases increased their response to iron therapy.
authors.affiliation: Department of Internal Medicine, Ain Shams University, Cairo, Egypt.
authors.forename: Ehab H
authors.initials: EH
authors.lastname: Nashaat
authors.forename: Ghada M
authors.initials: GM
authors.lastname: Mansour
mesh_terms: D000328:Adult; D000667:Ampicillin / Q000627:therapeutic use; D018798:Anemia, Iron-Deficiency / Q000188:drug therapy*; D000890:Anti-Infective Agents / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005293:Ferritins / Q000097:blood; D005296:Ferrous Compounds / Q000627:therapeutic use; D005998:Glycine / Q000627:therapeutic use; D018684:Glycine Agents / Q000627:therapeutic use; D016481:Helicobacter Infections / Q000097:blood / Q000188:drug therapy*; D016480:Helicobacter pylori; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007501:Iron / Q000097:blood; D008795:Metronidazole / Q000627:therapeutic use; D009853:Omeprazole / Q000627:therapeutic use; D011247:Pregnancy / Q000097:blood; D011250:Pregnancy Complications, Hematologic / Q000097:blood / Q000188:drug therapy*; D011251:Pregnancy Complications, Infectious / Q000097:blood / Q000188:drug therapy*; D054328:Proton Pump Inhibitors / Q000627:therapeutic use
chemical_list: D000890:Anti-Infective Agents; D005296:Ferrous Compounds; D018684:Glycine Agents; D006454:Hemoglobins; D054328:Proton Pump Inhibitors; D008795:Metronidazole; D000667:Ampicillin; D005293:Ferritins; D007501:Iron; D009853:Omeprazole; D005998:Glycine